Pharmacologic Management of COPD - American Thoracic Society Clinical Practice Guideline

Pharmacologic treatment for COPD aims to improve quality of life, control symptoms, and reduce the frequency of exacerbations. The pharmacological treatment of COPD includes bronchodilators to relax smooth muscle, such as β2-agonists, short-acting β2-agonists and long-acting β2-agonists as well as short and long-acting anticholinergics. The American Thoracic Society has formulated guidelines on the pharmacological management of COPD. Please share your thoughts on the same.......

10 Likes

LikeAnswersShare

Currently there is no treatment of COPD, treatment can slow down the progress of COPD short term inhalers sop smoking bronchodilaters including phosphodiaestrase can help steroids has limited role but must be used in emergency conditions

Jo janta nahi vo kya teatment karega
0

Deep insight in treatment ofCOPD Guidelines discussed given by ATS Yes LABA/LAMA dual therapy for consistent management is necessary add on ICS also quite indicated and useful This reduces frequency of episodes and hospitalisation Yes incidences of pneumonitis is concern as expiration is less and fev1 decreased in copd increases incidences of infection and pneumonitis With inhalers quality of life improves and oral medication dependence decreases

Thanx dr Sonia Ahuja
0

View 1 other reply

Informative and educative post. Proper diagnosis improve quality of life. Breathing exercise can be helpful.

Thanks Dr Dinesh Gupta
0

View 3 other replies

Nice informative article on COPD.

NICE ILLUSTRATION COPD IS A VERY COMMON PULMONARY DESEASE MAY BE GENETIC CHRONIC SMOKING AT PRESENT DUE TO COVID 19 PANDEMIC COPD CAN BE SEVERE

C O P D .NEEDS TIMELY. INVESTIGATION AND DIAGNOSIS.... PLAYS. THE. IMPORTANT. ROLE. IN IMPROVING. THE. QUALITY. OF. LIFE

Pharmacological Management of COPD - American Thoracic Society Clinical Practice Guideline. Nice Usefull Update & Illustration.

Background: Evidence-based guidelines are needed for effective delivery of home oxygen therapy to appropriate patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Methods: The multidisciplinary panel created six research questions using a modified Delphi approach. A systematic review of the literature was completed, and the Grading of Recommendations Assessment, Development and Evaluation approach was used to formulate clinical recommendations. Recommendations: The panel found varying quality and availability of evidence and made the following judgments: 1) strong recommendations for long-term oxygen use in patients with COPD (moderate-quality evidence) or ILD (low-quality evidence) with severe chronic resting hypoxemia, 2) a conditional recommendation against long-term oxygen use in patients with COPD with moderate chronic resting hypoxemia, 3) conditional recommendations for ambulatory oxygen use in patients with COPD (moderate-quality evidence) or ILD (low-quality evidence) with severe exertional hypoxemia, 4) a conditional recommendation for ambulatory liquid-oxygen use in patients who are mobile outside the home and require >3 L/min of continuous-flow oxygen during exertion (very-low-quality evidence), and 5) a recommendation that patients and their caregivers receive education on oxygen equipment and safety (best-practice statement). Conclusions: These guidelines provide the basis for evidence-based use of home oxygen therapy in adults with COPD or ILD but also highlight the need for additional research to guide clinical practice. Background: This document provides clinical recommendations for the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative effort on the part of a panel of expert COPD clinicians and researchers along with a team of methodologists under the guidance of the American Thoracic Society. Methods: Comprehensive evidence syntheses were performed on all relevant studies that addressed the clinical questions and critical patient-centered outcomes agreed upon by the panel of experts. The evidence was appraised, rated, and graded, and recommendations were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results: After weighing the quality of evidence and balancing the desirable and undesirable effects, the guideline panel made the following recommendations: 1) a strong recommendation for the use of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy in patients with COPD and dyspnea or exercise intolerance; 2) a conditional recommendation for the use of triple therapy with inhaled corticosteroids (ICS)/LABA/LAMA over dual therapy with LABA/LAMA in patients with COPD and dyspnea or exercise intolerance who have experienced one or more exacerbations in the past year; 3) a conditional recommendation for ICS withdrawal for patients with COPD receiving triple therapy (ICS/LABA/LAMA) if the patient has had no exacerbations in the past year; 4) no recommendation for or against ICS as an additive therapy to long-acting bronchodilators in patients with COPD and blood eosinophilia, except for those patients with a history of one or more exacerbations in the past year requiring antibiotics or oral steroids or hospitalization, for whom ICS is conditionally recommended as an additive therapy; 5) a conditional recommendation against the use of maintenance oral corticosteroids in patients with COPD and a history of severe and frequent exacerbations; and 6) a conditional recommendation for opioid-based therapy in patients with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy. Conclusions: The task force made recommendations regarding the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are underrepresented in clinical trials is needed, including studies in patients with COPD 80 years of age and older, those with multiple chronic health conditions, and those with a codiagnosis of COPD and asthma.

COPD .. should be diagnosed and treated as per norms. Physical fitness and yoga , breathing exercises and good food with antioxidant are recommended . Inhalers are best suitable in COPD patients

Laba Lama Ics Aim of treatment

Load more answers

Cases that would interest you